Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642994 | 0.94 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6639239 | 0.93 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6640813 | 0.93 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6642349 | 0.82 | SRC (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6639275 | 0.81 | SRC (0.86) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6641068 | 0.81 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6642981 | 0.81 | FGFR1 (1.00) | FGFR1SRCEGFR | |
| SCHEMBL6640958 | 0.81 | FGFR1 (1.00) | FGFR1SRC | |
| SCHEMBL6641180 | 0.80 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL6640511 | 0.79 | FGFR1 (1.00) | FGFR1SRCEGFRFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003745-B1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2004-12-29 | — | — | EP | claimed |
| US-6150359-A | 1,6-NAPHTHYRIDIONE COMPOUNDS USEFUL FOR TREATING CANCER, RESTENOSIS AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-11-21 | — | — | US | claimed |
| EP-1003745-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999009030-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-1003745-B1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6150359-A | 1,6-NAPHTHYRIDIONE COMPOUNDS USEFUL FOR TREATING CANCER, RESTENOSIS AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1003745-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009030-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |